Cage Pharma (http://www.cagephar.ma) is a biopharmaceutical company focused on the development of compounds targeting tumor metabolism.
Cage’s lead compound, CP-102, is a systemically administered anticancer agent that exclusively targets cancer by directly attacking one of its key hallmarks, tumor glycolysis. Glycolysis is the main metabolic pathway used by cancer cells to generate energy, and because cancer cells rely almost exclusively on glycolysis for their energy needs, they are especially vulnerable to a drug that specifically targets it. Importantly, CP-102 has been found to not impact healthy cells, as they rely on a different metabolic pathway that does not create the same target as cancer cells. In addition to the anticancer effect, CP-102 is accompanied by a built-in biomarker to identify and select cancer types most likely to respond to treatment. We have initially identified pancreatic cancer, colorectal cancer, sarcoma, and cholangiocarcinoma as Phase 1 target populations. The company has repeatedly confirmed CP-102’s efficacy and safety in in vivo models, and is now working through its manufacturing and IND initiatives to reach the clinic in a Phase 1 study in 2020.